128 related articles for article (PubMed ID: 38343206)
1. Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria.
Zubiaga-Fernandez L; Testera-Montes A; Rondon C; Perez-Sanchez N; Gomez-Perez F; Vega-Chicote JM; Bartra J; Ferrer M; Eguiluz-Gracia I; Torres MJ
Clin Exp Allergy; 2024 Jun; 54(6):402-411. PubMed ID: 38343206
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
[TBL] [Abstract][Full Text] [Related]
3. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.
MacGlashan D; Saini S; Schroeder JT
J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077
[TBL] [Abstract][Full Text] [Related]
4. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria.
Hoşgören-Tekin S; Eyüboğlu İP; Akkiprik M; Giménez-Arnau AM; Salman A
Arch Dermatol Res; 2024 May; 316(6):261. PubMed ID: 38795119
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation.
Brás R; Costa C; Limão R; Caldeira LE; Paulino M; Pedro E
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2392-2402. PubMed ID: 36720390
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the long-term economic burden of omalizumab on patients with chronic spontaneous urticaria.
Matsubara D; Takahagi S; Saito R; Kamegashira A; Tanaka A; Hide M
J Dermatol; 2021 Jan; 48(1):56-63. PubMed ID: 33029864
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?
Kocatürk E; Başkan EB; Küçük ÖS; Özdemir M; Örnek S; Can PK; Haşal E; Engin B; Atakan N; Alpsoy E
An Bras Dermatol; 2022; 97(5):592-600. PubMed ID: 35853771
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
[No Abstract] [Full Text] [Related]
11. The Real-Life Effectiveness and Safety of Omalizumab Updosing in Patients With Chronic Spontaneous Urticaria.
Salman A; Comert E
J Cutan Med Surg; 2019; 23(5):496-500. PubMed ID: 31030540
[TBL] [Abstract][Full Text] [Related]
12. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
Magen E; Waitman DA; Kahan NR
Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
[No Abstract] [Full Text] [Related]
13. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.
Jeong SH; Lim DJ; Chang SE; Kim KH; Kim KJ; Park EJ
J Korean Med Sci; 2022 Jul; 37(27):e211. PubMed ID: 35818702
[TBL] [Abstract][Full Text] [Related]
14. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
Brás R; Esteves Caldeira L; Bernardino A; Costa C
Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
[TBL] [Abstract][Full Text] [Related]
15. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
[TBL] [Abstract][Full Text] [Related]
16. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.
Kaplan A; Ferrer M; Bernstein JA; Antonova E; Trzaskoma B; Raimundo K; Rosén K; Omachi TA; Khalil S; Zazzali JL
J Allergy Clin Immunol; 2016 Feb; 137(2):474-81. PubMed ID: 26483177
[TBL] [Abstract][Full Text] [Related]
17. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
[TBL] [Abstract][Full Text] [Related]
19. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
Salman A; Demir G; Bekiroglu N
Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
[TBL] [Abstract][Full Text] [Related]
20. Are currently available biomarkers useful to discriminate CSU patients not controlled by low dose omalizumab maintenance therapy?
Asero R
Eur Ann Allergy Clin Immunol; 2020 Nov; 52(6):268-270. PubMed ID: 32191021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
